LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 70

Search options

  1. Article ; Online: Systematic review and meta-analysis of autologous stem cell transplantation in peripheral T cell lymphoma.

    Gurion, Ronit

    Acta haematologica

    2014  Volume 131, Issue 2, Page(s) 112–113

    MeSH term(s) Humans ; Lymphoma, T-Cell, Peripheral/surgery ; Stem Cell Transplantation
    Language English
    Publishing date 2014
    Publishing country Switzerland
    Document type Comment ; Editorial
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000354818
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Presence and activity of Fibrinogen like protein 2 in platelets.

    Cherny, Izhack / Hasin, Pinhas / Philosoph, Lital Kalich / Shahal-Zimra, Yael / Gurion, Ronit / Rabizadeh, Esther

    PloS one

    2023  Volume 18, Issue 5, Page(s) e0285735

    Abstract: Background: Fibrinogen-like protein 2 (FGL2) is a serine protease capable of converting prothrombin into thrombin (i.e., prothrombinase-like activity) while bypassing the classic coagulation cascade. It has been reported to be expressed by mononuclear ... ...

    Abstract Background: Fibrinogen-like protein 2 (FGL2) is a serine protease capable of converting prothrombin into thrombin (i.e., prothrombinase-like activity) while bypassing the classic coagulation cascade. It has been reported to be expressed by mononuclear blood cells and endothelial cells. There are multiple reports that FGL2 supports tumor development and metastasis. However, in the blood, the origin and functional significance of FGL2 has not been established.
    Objective: To determine if FGL2, a malignancy related enzyme, is present in platelets.
    Methods: Peripheral blood samples were collected in K2 EDTA tubes. Blood cells and platelets were separated and thoroughly washed to produce plasma-free samples. Procoagulant activity was measured in the cell lysates using a thrombin generation test or an adjusted prothrombin time (PT) test in plasma deficient of factor X. The findings were further supported by confocal microscopy, immunoprecipitation, flow cytometry, enzyme-linked immunosorbent assays and specific inhibition assays.
    Results: FGL2 protein was readily detected in platelets. Also, despite being expressed by lymphocytes, FGL2 prothrombinase-like activity was solely detected in platelet samples, but not in white blood cell samples. Quiescent platelets were shown to contain the FGL2 protein in an active form. Upon activation, platelets secreted the active FGL2 into the milieu.
    Conclusions: Active FGL2 is found in platelets. This suggests another role for the involvement of platelets in malignancies.
    MeSH term(s) Blood Coagulation ; Blood Platelets/metabolism ; Endothelial Cells/metabolism ; Fibrinogen/metabolism ; Thrombin/metabolism ; Thromboplastin/metabolism ; Humans
    Chemical Substances Fibrinogen (9001-32-5) ; Thrombin (EC 3.4.21.5) ; Thromboplastin (9035-58-9) ; FGL2 protein, human
    Language English
    Publishing date 2023-05-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0285735
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.

    Shargian, Liat / Raanani, Pia / Yeshurun, Moshe / Gafter-Gvili, Anat / Gurion, Ronit

    British journal of haematology

    2022  Volume 200, Issue 1, Page(s) e4–e5

    MeSH term(s) Humans ; Receptors, Chimeric Antigen ; Standard of Care ; Immunotherapy, Adoptive ; Lymphoma, Large B-Cell, Diffuse/therapy ; Cell- and Tissue-Based Therapy ; Antigens, CD19 ; Receptors, Antigen, T-Cell
    Chemical Substances Receptors, Chimeric Antigen ; Antigens, CD19 ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2022-10-25
    Publishing country England
    Document type Meta-Analysis ; Systematic Review ; Letter ; Comment
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18506
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Presence and activity of Fibrinogen like protein 2 in platelets.

    Izhack Cherny / Pinhas Hasin / Lital Kalich Philosoph / Yael Shahal-Zimra / Ronit Gurion / Esther Rabizadeh

    PLoS ONE, Vol 18, Iss 5, p e

    2023  Volume 0285735

    Abstract: Background Fibrinogen-like protein 2 (FGL2) is a serine protease capable of converting prothrombin into thrombin (i.e., prothrombinase-like activity) while bypassing the classic coagulation cascade. It has been reported to be expressed by mononuclear ... ...

    Abstract Background Fibrinogen-like protein 2 (FGL2) is a serine protease capable of converting prothrombin into thrombin (i.e., prothrombinase-like activity) while bypassing the classic coagulation cascade. It has been reported to be expressed by mononuclear blood cells and endothelial cells. There are multiple reports that FGL2 supports tumor development and metastasis. However, in the blood, the origin and functional significance of FGL2 has not been established. Objective To determine if FGL2, a malignancy related enzyme, is present in platelets. Methods Peripheral blood samples were collected in K2 EDTA tubes. Blood cells and platelets were separated and thoroughly washed to produce plasma-free samples. Procoagulant activity was measured in the cell lysates using a thrombin generation test or an adjusted prothrombin time (PT) test in plasma deficient of factor X. The findings were further supported by confocal microscopy, immunoprecipitation, flow cytometry, enzyme-linked immunosorbent assays and specific inhibition assays. Results FGL2 protein was readily detected in platelets. Also, despite being expressed by lymphocytes, FGL2 prothrombinase-like activity was solely detected in platelet samples, but not in white blood cell samples. Quiescent platelets were shown to contain the FGL2 protein in an active form. Upon activation, platelets secreted the active FGL2 into the milieu. Conclusions Active FGL2 is found in platelets. This suggests another role for the involvement of platelets in malignancies.
    Keywords Medicine ; R ; Science ; Q
    Subject code 630
    Language English
    Publishing date 2023-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.

    Shargian, Liat / Raanani, Pia / Yeshurun, Moshe / Gafter-Gvili, Anat / Gurion, Ronit

    British journal of haematology

    2022  Volume 198, Issue 5, Page(s) 838–846

    Abstract: Treatment with high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered standard of care (SOC) second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL). However, outcomes remain suboptimal. A ... ...

    Abstract Treatment with high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered standard of care (SOC) second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL). However, outcomes remain suboptimal. A systematic review and meta-analysis of randomised controlled trials comparing efficacy and safety of SOC versus chimeric antigen receptor T-cell (CAR-T) therapy as second-line for patients with LBCL refractory or relapsing within 12 months. Outcomes included overall survival (OS), event-free survival (EFS), overall response rate (ORR) and safety. Three trials published in 2021 (involving 865 participants) fulfilled the eligibility criteria. EFS as well as OS were significantly improved with CAR-T therapy as compared to SOC, hazard ratio (HR) 0.57 (95% confidence interval [CI] 0.49-0.68) and HR 0.77 (95% CI 0.60-0.98) respectively. CAR-T therapy was associated with significantly better ORR, relative risk (RR) 1.55 (95% CI 1.12-2.13, p = 0.001). The risk of Grade III/IV adverse event was comparable between the two arms, RR 1.03 (95% CI 0.93-1.14). In summary, CAR-T therapy has superior outcomes as compared to SOC in patients with LBCL refractory or relapsing within 12 months, without excess of toxicity. Longer follow-up is needed to confirm these results and determine the optimal sequencing of CAR-T therapy in the management of LBCL.
    MeSH term(s) Antigens, CD19 ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy, Adoptive/methods ; Lymphoma, Large B-Cell, Diffuse/etiology ; Lymphoma, Large B-Cell, Diffuse/therapy ; Neoplasm Recurrence, Local/therapy ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen ; Standard of Care ; Transplantation, Autologous
    Chemical Substances Antigens, CD19 ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2022-06-28
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Systematic Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18335
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Right Coronary Artery "Vessel Floating Sign" in a Patient With Primary Cardiac Lymphoma.

    Kheifets, Mark / Shafir, Gideon / Gurion, Ronit / Raanani, Pia / Kornowski, Ran / Levi, Amos

    JACC. Case reports

    2021  Volume 3, Issue 13, Page(s) 1524–1526

    Abstract: Primary cardiac lymphoma is a rare and lethal tumor. We describe a patient with right coronary artery floating sign, a specific radiologic sign. Despite rapid diagnosis and guideline-directed medical therapy, disease relapsed and the patient died. ... ...

    Abstract Primary cardiac lymphoma is a rare and lethal tumor. We describe a patient with right coronary artery floating sign, a specific radiologic sign. Despite rapid diagnosis and guideline-directed medical therapy, disease relapsed and the patient died. Nevertheless, this case highlights the crucial role of imaging in cardiac tumors. (
    Language English
    Publishing date 2021-10-06
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2666-0849
    ISSN (online) 2666-0849
    DOI 10.1016/j.jaccas.2021.08.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Systematic Review and Meta-Analysis of Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma

    Gurion, Ronit

    Acta Haematologica

    2013  Volume 131, Issue 2, Page(s) 112–113

    Institution Institute of Hematology, Davidoff Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Language English
    Publishing date 2013-10-19
    Publisher S. Karger AG
    Publishing place Basel, Switzerland
    Document type Article
    Note Editorial Comment
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000354818
    Database Karger publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis.

    Pasvolsky, Oren / Rozental, Alon / Raanani, Pia / Gafter-Gvili, Anat / Gurion, Ronit

    Acta oncologica (Stockholm, Sweden)

    2021  Volume 60, Issue 6, Page(s) 744–749

    Abstract: Background: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard of care first line treatment for diffuse large B-cell lymphoma (DLBCL), though outcomes remain suboptimal.: Methods: We performed a ... ...

    Abstract Background: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard of care first line treatment for diffuse large B-cell lymphoma (DLBCL), though outcomes remain suboptimal.
    Methods: We performed a systemic review and meta-analysis of randomized controlled trials comparing the efficacy and safety of R-CHOP vs. R-CHOP + X (addition of another drug to R-CHOP) as first line treatment for DLBCL. We searched Cochrane Library, PubMed and conference proceedings up to September 2020.
    Results: Our search yielded ten trials including 4206 patients. The added drug was bortezomib or lenalidomide in three trials each, and gemcitabine, bevacizumab and ibrutinib, each drug in one trial. R-CHOP + X was associated with statistically significant improved disease control (HR 0.88, 95% CI 0.78-0.99). The point estimate was in favor of improved overall survival with R-CHOP + X (hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.75-1.00), although this was not statistically significant. Subgroup analysis revealed improved disease control with the addition of lenalidomide and in patients younger than 60 years. R-CHOP + X was associated with an increase in serious adverse events and grade III/IV hematologic toxicity.
    Conclusion: The addition of another drug to frontline R-CHOP treatment for DLBCL did not result in a significant improvement in OS, although we did observe improved disease control compared to R-CHOP, perhaps most evident with the addition of lenalidomide. Yet, RCHOP + X was associated with an increased risk for serious and hematological adverse events. Further studies could reveal subgroups that would benefit most from augmentation of standard R-CHOP.
    MeSH term(s) Antibodies, Monoclonal, Murine-Derived/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/adverse effects ; Doxorubicin/adverse effects ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Prednisone/adverse effects ; Rituximab/therapeutic use ; Vincristine/adverse effects
    Chemical Substances Antibodies, Monoclonal, Murine-Derived ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2021-03-18
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 896449-x
    ISSN 1651-226X ; 0349-652X ; 0284-186X ; 1100-1704
    ISSN (online) 1651-226X
    ISSN 0349-652X ; 0284-186X ; 1100-1704
    DOI 10.1080/0284186X.2021.1898048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6348: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma: a nationwide survey and retrospective study.

    Berger, Tamar / Geiger, Karyn Revital / Yeshurun, Moshe / Gafter-Gvili, Anat / Shochat, Tzippy / Gurion, Ronit / Raanani, Pia / Pasvolsky, Oren

    Leukemia & lymphoma

    2022  Volume 63, Issue 10, Page(s) 2461–2468

    Abstract: Almost half of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed/refractory (R/R) disease after frontline immunochemotherapy. Although guidelines recommend histological confirmation of R/R disease, repeat biopsies are not always performed. ...

    Abstract Almost half of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed/refractory (R/R) disease after frontline immunochemotherapy. Although guidelines recommend histological confirmation of R/R disease, repeat biopsies are not always performed. We conducted a two-part study: a nationwide case-vignette survey among treating hematologists, and a single center retrospective analysis. In the survey part, all 64 participating physicians opted not to perform a repeat biopsy in at least one scenario, more often in refractory cases. In the retrospective part, 116 episodes of R/R aNHL among 61 patients were identified. Repeat biopsy was not performed in 72%, more often in refractory episodes, mostly due to low likelihood of alternative diagnoses or problematic location for biopsy. Our study suggests that many patients do not undergo repeat biopsy in R/R DLBCL, especially in refractory cases. Future studies and recommendations should address the necessity of repeat biopsy, according to patient and disease related characteristics.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biopsy ; Humans ; Immunotherapy ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/therapy ; Lymphoma, Non-Hodgkin/drug therapy ; Retrospective Studies
    Language English
    Publishing date 2022-05-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2022.2081325
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.

    Bairey, Osnat / Lebel, Eyal / Buxbaum, Chen / Porges, Tzvika / Taliansky, Alisa / Gurion, Ronit / Goldschmidt, Neta / Shina, Tzahala Tzuk / Zektser, Miri / Hofstetter, Liron / Siegal, Tali

    Hematological oncology

    2023  Volume 41, Issue 5, Page(s) 838–847

    Abstract: Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large retrospective studies on this rare disease may yield ... ...

    Abstract Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large retrospective studies on this rare disease may yield information that might prove useful for the future design of randomized clinical trials. We retrospectively analyzed the data of 222 newly diagnosed PCNSL patients treated in five referral centers in Israel between 2001 and 2020. During this period, combination therapy became the treatment of choice, rituximab has been added to the induction therapy, and consolidation with irradiation was largely laid off and was mostly replaced by high-dose chemotherapy with or without autologous stem cell transplantation (HDC-ASCT). Patients older than 60 comprised 67.5% of the study population. First-line treatment included high-dose methotrexate (HD-MTX) in 94% of patients with a median MTX dose of 3.5 g/m
    MeSH term(s) Humans ; Retrospective Studies ; Rituximab/therapeutic use ; Hematopoietic Stem Cell Transplantation/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Prospective Studies ; Rare Diseases/drug therapy ; Rare Diseases/etiology ; Central Nervous System Neoplasms/drug therapy ; Transplantation, Autologous ; Methotrexate ; Lymphoma/pathology ; Central Nervous System/pathology
    Chemical Substances Rituximab (4F4X42SYQ6) ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2023-07-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3198
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1816: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top